Bioethicists Advocate Cost Criterion For Coverage With Evidence Development
This article was originally published in The Gray Sheet
Executive Summary
Pricier medical technologies might be better candidates for Medicare coverage conditioned on collection of evidence than less costly products, National Institutes of Health bioethicists suggest
You may also be interested in...
Questions Linger Over Coverage-With-Evidence-Development Guidance
CMS' latest direction on coverage with evidence development has small manufacturers still guessing how far the agency intends to extend its oversight and how much of the burden of fulfilling CMS' goals will fall to firms
CMS Offers Two Paths To “Coverage With Evidence” In Revised Guidance
CMS introduces two distinct categories of coverage-with-evidence-development determinations in long-awaited 1guidelines issued July 12
Imaging Registry Begins: Coverage-With-Evidence Policy Gets A Second Wind
The May 8 commencement of a nationwide positron emission tomography imaging registry is an important step forward for CMS' fledgling coverage-with-evidence-development (CED) policy, not to mention for expanded use of PET scans